title: Triple therapy of intravitreal triamcinolone, photodynamic therapy, and pegaptanib sodium for choroidal neovascularization.
abstract: OBJECTIVE
  To report the six-month results of subfoveal choroidal neovascularization that had been treated with combined therapy of high-dose intravitreal triamcinolone acetonide (HDIVTA), photodynamic therapy (PDT), and pegaptanib sodium injection.
  
  
  METHODS
  Retrospective, interventional case series study.
  
  
  METHODS
  Medical files of 16 patients with this treatment were reviewed (22 eyes); 13 eyes had had previous treatment with HDIVTA and PDT; nine eyes were newly diagnosed choroidal neovascularization. Patients were treated with an injection of HDIVTA (10 mg), followed by PDT and pegabtanib sodium injection at two-week intervals. The main outcome variables were visual acuity (VA) and macular thickness by optical coherence tomography (OCT).
  
  
  RESULTS
  The mean VA improved 2.2 lines (P = .013 in the new treatment group); the previous treatment group (HDIVTA + PDT) improved only 0.7 lines (P = 0.55, Wilcoxon ranked test). The mean of macular thickness before and after treatment was statistically significant in both groups.
  
  
  CONCLUSIONS
  This combination therapy showed improvement and/or stabilization in VA, particularly when used as first-line therapy.
authors.affiliation: New England Retina Research and Education Foundation, Hamden, Connecticut; Yale Eye Center, New Haven, Connecticut 06518, USA.
authors.forename: Peter E
authors.initials: PE
authors.lastname: Liggett
authors.forename: Juner
authors.initials: J
authors.lastname: Colina
authors.forename: Nauman A
authors.initials: NA
authors.lastname: Chaudhry
authors.forename: David
authors.initials: D
authors.lastname: Tom
authors.forename: Gregory
authors.initials: G
authors.lastname: Haffner
mesh_terms: D000369:Aged, 80 and over; D052157:Aptamers, Nucleotide / Q000627:therapeutic use*; D020256:Choroidal Neovascularization / Q000175:diagnosis / Q000188:drug therapy*; D004359:Drug Therapy, Combination; D005451:Fluorescein Angiography; D005938:Glucocorticoids / Q000627:therapeutic use*; D006801:Humans; D007267:Injections; D010778:Photochemotherapy; D017319:Photosensitizing Agents / Q000627:therapeutic use; D011166:Porphyrins / Q000627:therapeutic use; D012189:Retrospective Studies; D041623:Tomography, Optical Coherence; D016896:Treatment Outcome; D014222:Triamcinolone Acetonide / Q000627:therapeutic use*; D042461:Vascular Endothelial Growth Factor A / Q000037:antagonists & inhibitors; D000077362:Verteporfin; D014792:Visual Acuity; D014822:Vitreous Body
chemical_list: D052157:Aptamers, Nucleotide; D005938:Glucocorticoids; D017319:Photosensitizing Agents; D011166:Porphyrins; C467484:VEGFA protein, human; D042461:Vascular Endothelial Growth Factor A; D000077362:Verteporfin; C495058:pegaptanib; D014222:Triamcinolone Acetonide